Company Overview - I-Mab Sponsored ADR (IMAB) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Price Performance - IMAB shares have increased by 4.52% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 0.67% [5] - Over the past month, IMAB's price change is 121.68%, significantly higher than the industry's 0.85% performance [5] - In the last quarter, IMAB shares have surged by 151.4%, and over the past year, they have gained 284.61%, while the S&P 500 has only moved 9.72% and 16.49% respectively [6] Trading Volume - The average 20-day trading volume for IMAB is 4,790,854 shares, which is a useful indicator of market interest and momentum [7] Earnings Outlook - In the past two months, one earnings estimate for IMAB has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$0.44 to -$0.41 [9] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [9] Conclusion - Given the strong price performance, positive earnings outlook, and high momentum score, IMAB is positioned as a solid momentum pick for investors [11]

Core Viewpoint - Tianjing Bio (IMAB) is experiencing significant growth in revenue and is preparing to release its mid-year financial report for FY2024, indicating a focus on innovative biopharmaceuticals in oncology and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its FY2024 mid-year report on August 28, 2023, before the market opens in the Eastern US [2]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential in the global market [2]. - The company's mission is to create groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients worldwide [2].

Core Insights - I-Mab has appointed independent directors Dr. Robert Lenz and Ms. Xin Liu to its Board of Directors, effective August 22, 2025, and reiterated the appointment of Dr. Sean Cao as of May 28, 2025 [1][2][6] - The company has established a Research and Development Committee, chaired by Dr. Robert Lenz, to enhance its focus on R&D excellence and innovation [2][6] - Dr. Ken Takeshita has been appointed to the Scientific Advisory Board to strengthen I-Mab's capabilities in immuno-oncology [2][6] Company Developments - The new appointments are aimed at supporting I-Mab's strategic agenda and enhancing the Board's expertise as the company progresses with its lead product, givastomig [2][6] - Givastomig is a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers, currently in Phase 1 trials, showing strong tumor-binding and anti-tumor activity [8] Board Member Profiles - Dr. Robert Lenz has extensive experience in R&D, previously serving as Executive Vice President at Neumora Therapeutics and holding key roles at Amgen and Abbott Laboratories [2][3] - Ms. Xin Liu is a finance executive with a background in healthcare investments, currently serving as Investment Director at Hony Capital [3][4] - Dr. Sean Cao is a biotech entrepreneur with a strong background in founding and leading biotech companies, currently an Operating Partner at CBC Group [4][5] - Dr. Ken Takeshita is a recognized biopharmaceutical executive with experience in clinical development and research, currently the Global Head of R&D for Daiichi Sankyo [5][6]

Core Insights - Tianjing Bio (IMAB) opened with a 5.94% increase on August 22, reaching $4.99 per share, with a total market capitalization of $574 million [1] - The company reported total revenue of 27.644 million RMB for the year ending December 31, 2023, representing a year-on-year growth of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Company Overview - Tianjing Bio is an offshore holding company registered abroad, operating through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2] - The company's mission is to develop groundbreaking innovative biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, prior to the market opening [2]

Core Viewpoint - Tianjing Bio (IMAB) has shown significant growth in revenue and is preparing to release its fiscal year 2024 mid-term report, indicating a focus on innovative biopharmaceuticals in oncology and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1]. - The company's mission is to create groundbreaking innovative biopharmaceuticals to address unmet clinical needs and improve the quality of life for patients globally [1].

Core Viewpoint - I-Mab is actively participating in investor conferences in September 2025 to engage with potential investors and showcase its innovative pipeline in precision immuno-oncology for cancer treatment [1][2]. Group 1: Conference Participation - I-Mab's management team will attend the Cantor Global Healthcare Conference from September 3-5, 2025, focusing on one-on-one meetings [1]. - The company will also present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:30 AM ET, which will include a company presentation and one-on-one meetings [2]. Group 2: Company Overview - I-Mab is a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment [3]. - The company's leading product candidate, givastomig, is a bispecific antibody targeting Claudin 18.2, designed for treating Claudin 18.2-positive gastric cancers [3]. - Givastomig is currently in Phase 1 trials, demonstrating strong tumor-binding and anti-tumor activity while minimizing common toxicities associated with other 4-1BB agents [3].

Core Insights - Tianjing Bio (IMAB) opened with a 10.2% increase, reaching $4.64 per share, with a total market capitalization of $534 million [1] - The company reported total revenue of 27.644 million RMB for the year ending December 31, 2023, representing a year-on-year growth of 112.48% [1] - The net profit attributable to the parent company was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Financial Performance - Revenue for 2023 was 27.644 million RMB, up 112.48% compared to the previous year [1] - The net profit attributable to the parent company was -1.466 billion RMB, an increase of 41.54% year-on-year [1] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunity and autoimmune diseases [1] - The company's mission is to develop groundbreaking innovative biopharmaceuticals to address unmet clinical needs and improve the quality of life for patients globally [1] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [1]

Exhibit 99.1 I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update ROCKVILLE, MD, August 20, 2025 – I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2025, and highlighted recent pipeline progress and business updates. "The first half of 2025 has been transformative for I-Mab," sai ...

Core Insights - I-Mab has reported transformative progress in the first half of 2025, particularly with the promising Phase 1b combination data for its drug givastomig, which targets Claudin 18.2 for metastatic gastric cancers [2][3] Financial Performance - For the three months ended June 30, 2025, the company reported a net loss of $5.5 million, compared to a net loss of $8.9 million for the same period in 2024 [16] - For the six months ended June 30, 2025, the net loss was $8.7 million, an improvement from a net loss of $18.4 million in the same period in 2024 [16] - Research and development expenses decreased to $3.3 million for the three months ended June 30, 2025, down from $5.2 million in 2024 [10] - Administrative expenses also decreased to $3.8 million for the three months ended June 30, 2025, compared to $11.9 million in 2024 [11] Cash Position - As of June 30, 2025, I-Mab had cash and cash equivalents of $165.6 million, which is expected to fund operations through the fourth quarter of 2028 [7][6] - The company raised approximately $61.2 million from an underwritten offering in August 2025, strengthening its balance sheet [6] Clinical Developments - Givastomig demonstrated an 83% objective response rate in a Phase 1b study when combined with immunochemotherapy, with topline data expected in Q1 2026 [3][6] - The company has completed enrollment for the Phase 1b dose expansion study of givastomig in combination with nivolumab and mFOLFOX6 for first-line metastatic gastric cancers [3] Upcoming Milestones - I-Mab anticipates updates in 2026 for other programs, including ragistomig and uliledlimab, which are under development by ABL Bio and TJ Biopharma, respectively [4] Shareholder Information - As of June 30, 2025, the company had 188,108,178 ordinary shares outstanding, which will increase to 264,774,837 shares post-offering [8][9]

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year increase of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to create groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].